|Bid||0.00 x 800|
|Ask||0.00 x 4000|
|Day's Range||107.27 - 108.59|
|52 Week Range||58.59 - 110.70|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||13.31|
|Earnings Date||Jan 29, 2020 - Feb 3, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||103.40|
Bristol-Myers shares edged higher Monday after the group said a new cancer treatment, which it acquired through its $74 billion takeover of Celgene Corp., had solid results from an early clinical trial. Bristol-Myers said a study presented to the American Society of Hematology Conference in Orlando, Florida showed a 53% complete response rate for patients with relapsed or refractory large B-cell lymphoma treated with liso-cel. The new treatment, a so-called chimeric antigen receptor T-cell, or " CAR-T" therapy, was acquired from the immunotherapy portfolio of Celgene last year.
Bristol-Myers Squibb Co on Saturday said that an experimental cancer therapy it acquired as part of its $74 billion deal for Celgene Corp produced positive results in a clinical trial. The company said it will apply for U.S. approval for the treatment for a type of advanced blood cancer by the end of the year. The treatment, liso-cel, is a newer type of immunotherapy known as CAR-T cell therapy, that takes immune cells from a patient, engineers them to better recognize and attack cancer and infuses them back into the patient.
(Bloomberg) -- An experimental therapy from Bluebird Bio Inc. and Bristol-Myers Squibb Co. benefited more than 80% of patients nearing death from an advanced form of blood cancer in a pivotal study, clearing a hurdle in its path to U.S. approval.A single high-dose infusion of the personalized medicine known as bb2121 generated a response in 44 of 54 patients with multiple myeloma, including 19 who had a complete response, the companies said in a statement Friday. Patients went a median of 11.3 months before the cancer progressed, topping expectations that it needed to stop the disease for at least six months to gain approval from the U.S. Food and Drug Administration.Bluebird shares briefly jumped in late trading on Friday before surrendering most of their gains. The recently-issued CVR given in connection with the closing of Bristol-Myers’ deal with Celgene, known by the ticker BMY-R, rose 8.3%.The companies divulged the findings on the eve of the American Society of Hematology’s annual meeting in Orlando, Florida, where GlaxoSmithKline Plc., Regeneron Pharmaceuticals Inc. and Bristol’s own Celgene unit will present data on competing approaches. Cambridge, Massachusetts-based Bluebird and New York-based Bristol-Myers are scheduled to give an update on their next-generation therapy, bb21217, on Monday, while hotly anticipated results from competitor Johnson & Johnson’s Nanjing Legend Biotech-partnered therapy will take the spotlight that morning.The depth and the durability of the data “puts us in very good stead around any of the antibodies as well as other gene therapies,” Bluebird Chief Executive Officer Nick Leschly said. “We feel quite good about it, and that’s why we’re sprinting toward submission and driving toward earlier lines of therapy.”Positive results from the study, dubbed KarMMa, could lead to the first approval of the approach called CAR-T for patients with multiple myeloma, a deadly form of cancer found in white blood cells, wrote Raju Prasad, an analyst at William Blair, in a note. A response rate greater than 80% that can hold off the disease for at least 11 months would be well-received by doctors who might otherwise be wary of potential high costs and an aggressive approach, said Yaron Werber, an analyst at Cowen & Co.The approach known as CAR-T is already approved for a hard-to-treat form of pediatric leukemia and diffuse large B cell lymphoma, both blood cancers that are much less common than the multiple myeloma, which is diagnosed in about 30,000 Americans each year. Bluebird and Bristol’s therapy involves removing infection-fighting T cells from the blood, altering them to recognize a protein known as BCMA that is found in multiple myeloma cells, then putting them back into the patient to kill the cancer.(Updates with stock-price movement in third paragraph)\--With assistance from Tatiana Darie.To contact the reporters on this story: Bailey Lipschultz in New York at firstname.lastname@example.org;Michelle Fay Cortez in Minneapolis at email@example.comTo contact the editors responsible for this story: Catherine Larkin at firstname.lastname@example.org, Mark Schoifet, Timothy AnnettFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.
Moody's Investors Service ("Moody's") upgraded the senior unsecured ratings of Celgene Corporation to A3 from Baa2. Moody's anticipates that the ratings of Celgene will eventually be withdrawn. The upgrade of the ratings follows the recent acquisition of Celgene by Bristol-Myers Squibb Company ("Bristol") in which Celgene became a subsidiary of Bristol.
Pharmaceutical company Bristol-Myers has risen this year despite shareholder opposition to its Celgene buyout. Now that Bristol has officially acquired Celgene, is it time to buy BMY stock?
NanoString, which creates devices for molecular diagnostics and research tools to understand diseases and develop drugs, will record more than $100 million in revenue this year.
There may be sideways action in the drugmaker's shares in the near term, but a strong move higher is possible down the road.
The 700+ hedge funds and famous money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the third quarter, which unveil their equity positions as of September 30. We went through these filings, fixed typos and other more significant errors and identified the changes in hedge fund portfolios. Our extensive […]
Biotech stocks experienced some momentum last week amid a few clinical readouts. Karuna Therapeutics Inc (NASDAQ: KRTX ), which went public in June, was among the biggest gainers of the week on a positive ...
Bristol-Myers' (BMY) late-stage study evaluating the Opdivo-Yervoy combo fails to meet a co-primary endpoint of recurrence-free survival in melanoma patients. The company wraps up Celgene acquisition.
The contingent value rights debuted with a bang on the New York Stock Exchange Thursday, with heavy trading volume of 101 million amid selling by index funds.
Amgen raised its full-year outlook Thursday after the biotech company wrapped its acquisition of psoriasis treatment Otezla in the wake of Bristol-Myers Squibb's takeover of Celgene.
Amgen Inc on Thursday raised its full-year profit and revenue forecasts after completing its $13.4 billion acquisition of Celgene Corp's psoriasis therapy Otezla. Bristol-Myers Squibb Co, which completed its buyout of Celgene on Wednesday, had agreed to divest the drug for the merger to go through. Amgen now expects 2019 adjusted earnings per share between $14.50 and $14.70, up from its prior range of $14.20 to $14.45.
THOUSAND OAKS, Calif., Nov. 21, 2019 /PRNewswire/ -- Amgen (AMGN) today announced the successful completion of its acquisition of worldwide rights to Otezla® (apremilast), the only oral, non-biologic treatment for moderate-to-severe plaque psoriasis and psoriatic arthritis. Otezla was acquired from Celgene Corporation (CELG) in connection with its previously announced merger with Bristol-Myers Squibb Company (BMY), which was completed on Nov. 20. Otezla is an important treatment in the post-topical, pre-biologic segment in its approved indications in the U.S., including the treatment of patients with moderate-to-severe plaque psoriasis who are candidates for phototherapy or systemic therapy; adult patients with active psoriatic arthritis; and adult patients with oral ulcers associated with Behçet's Disease.
Bristol-Myers Squibb shares edged higher Thursday after the pharmaceutical group said it has completed its $74 billion acquisition of cancer drug specialist Celgene Corp.
Bristol-Myers Squibb Co. on Wednesday said it completed its $74 billion acquisition of Celgene Corp. , nearly a year after announcing the controversial deal. The completion comes after the Federal Trade Commission cleared the merger in a statement on Friday. The FTC required Bristol-Myers and Celgene sell the rights to Otezla, Celgene's psoriasis drug. Amgen Inc. agreed to buy the rights to the drug for $13.4 billion in August. Shares of Bristol-Myers and Celgene are up slight in after-hours trading on Wednesday.
(BMY)announced Wednesday that it had completed its acquisition of the biotech firm Celgene, nearly a year after announcing the controversial deal. The completion comes after the Federal Trade Commission effectively cleared the merger in a statement on Friday. As a condition of the deal, the FTC required Bristol-Myers (ticker: BMY) and Celgene (CELG) to sell the rights to Otezla, Celgene’s psoriasis drug.
Celgene Corporation announced today that following the completion of Celgene’s acquisition by Bristol-Myers Squibb Company , Bristol-Myers Squibb and Celgene plan to transfer the listing of Celgene’s contingent value rights that are related to Celgene’s ABRAXANE® product from the NASDAQ Global Market to the New York Stock Exchange .
NEW YORK , Nov. 19, 2019 /PRNewswire/ -- Thermo Fisher Scientific Inc. (NYSE:TMO) will replace Celgene Corp. (NASD: CELG) in the S&P 100, and ServiceNow Inc. (NYSE: NOW) will replace Celgene in the S&P ...